前列环素类药物治疗肺动脉高压的研究进展  

Advances in the Treatment of Pulmonary Arterial Hypertension with Prostacyclin and Its Analogs

作　　者：陈雨思 李江[1] CHEN Yusi;LI Jiang(Department of Cardiology,the Second Xiangya Hospital,Central South University,Changsha 410011,China)

机构地区：[1]中南大学湘雅二医院心血管内科,长沙410011

出　　处：《医药导报》2022年第2期195-200,共6页Herald of Medicine

基　　金：国家自然科学基金资助项目(81870233)。

摘　　要：肺动脉高压(PAH)是一类多种原因所致的、以肺小动脉异常收缩及重构为特征的恶性肺血管疾病,主要表现为肺血管阻力、肺动脉压力升高,最终导致右心功能衰竭甚至死亡。研究证实内源性前列环素减少与PAH的发生发展密切相关,针对前列环素通路的靶向药物不仅能改善PAH患者的症状,而且可以延缓甚至逆转疾病进展,改善患者远期预后。该文回顾该领域的相关文献,对前列环素类药物在PAH中的作用机制、临床应用、循证医学证据、治疗新策略及未来前景进行综述。Pulmonary arterial hypertension(PAH)is a malignant pulmonary vascular disease characterized by abnormal shrinkage and reconstruction of small pulmonary vessels.The progressive development of PAH usually leads to the increased pulmonary vascular resistance and pulmonary artery pressure,resulting in right ventricle failure and even death.Studies have shown that the decline of endogenous prostacyclin is related to the occurrence of pulmonary arterial hypertension,and drugs targeting prostacyclin pathway can not only improve the symptoms of patients with PAH but also slow down or reverse the progress of the disease and improve the long-term prognosis.This review discusses the mechanism of action,clinical application,evidence-based medicine,new therapeutic strategy,and future prospect of prostacyclin in pulmonary arterial hypertension.

关 键 词：肺动脉高压 依前列醇 伊洛前列素 曲前列尼尔 贝前列素钠 司来帕格 血管重构 

分 类 号：R972[医药卫生—药品] R543.2[医药卫生—药学]